Page 72 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Table 3. Eligibility criteria for enrollment in protocols with curative intent in chronological order of starting enrollment year (continued)
Center, Country Term used in Age Gleason score # biopsy PSA Imaging Stage Behavioral indication (other
[Pubmed ID] original article (yr) cores /% (ng/mL) than patients’ choice or
Enrollment years cores preference)
UCSF, US 111,133 AS – ≤6; no Cancer <10 – T1/T2a life
[18433013] Gleason involvement of expectancy
pattern 4 or 5 <33% of biopsy A priori exception: <15 >3 mo 133
>1991 cores for men with
A priori concurrent benign
exception: <50% of the prostatic hyperplasia
having a length of a tumor or prostatitis 133
Gleason score core involved by
of 4 reported carcinoma 133
only in a
microfocus of A priori exception:
tumor 133 having >33%
positive biopsy
cores due to a
tumor
microfocus 133
Royal Marsden AS – ≤7 (primary Less than half of ≤20 112 – T1–2, N0/X, –
Hospital, ≤3) the biopsy cores M0/X
UK 112,124,134 positive (octant <15 124
[15839912; <3+4 134 biopsy). 124
17850368]
<20% core
1993-2002; positive 134
≥2002; 124 2004-
2006 134
Johns Hopkins, AS (or EM – ≤6 ≤2 cores cancer PSA density (PSA TRUS to T1c –
US 113 with curative positive; ≤50% before diagnosis determine PSA
[20439642] intent) cancer in any divided by prostate density
single core volume) ≤0.15
1994-2008 ng/mL/cm3
b
Toronto-SRCC, WW; AS – ≤7 114 – ≤15 114 Chest X-ray, T1b-T2b N0 M0 –
Canada 114,125 TRUS of the (1997 TNM
c
[11395227; ≤6; ≤3+4 (if ≤10; <15 (if ≥70 prostate were classification)
19917860] ≥70 yr) 125 yr) 125 mandatory.
Bone scan and
1995-2002 as a CT scan of the
phase II trial; abdomen and
2003-ongoing as pelvis were
an open performed at
prospective the clinicians’
cohort discretion.

35